Molecule Shows Promise Against Atherothrombosis

Preclinical results of a molecule designed to combat atherothrombotic disease show that in treated mice, cholesterol levels dropped immediately, atheroma plaque showed signs of regression, and weight gain slowed.

Called Nimoxine, the molecule belongs to a family of molecules identified for their ability to reduce cholesterol and triglyceride levels. The molecule can be used to block the accumulation of lipids and macrophages that are central to the growth of vascular lesions in patients with atherothrombosis. Nimoxine is being developed by ClinicGenetics (Nimes, France), a biopharmaceutical company that is identifying and developing new targets and products for the treatment of cardiovascular disease.

"The excellent results obtained from these preclinical trials endorse our approach to finding valid treatments for atherothrombotic disease,” said Dr. Gerard Marguerie, vice president and CEO of CliniGenetics. Instead of focusing on the two traditional therapeutic pathways, statins or antithrombotic therapy, the company has identified a third pathway, "stabilization therapy,” designed for patients who cannot tolerate existing therapies or for whom these treatments prove of limited efficacy.




Related Links:
CliniGenetics